PCLX-001 (via Pacylex investment)

About Greenfire Bio

Greenfire Bio is a private, pre-revenue biotech company that functions as a specialized accelerator for early-stage oncology assets. Its business model involves acquiring or in-licensing late preclinical or early clinical programs, primarily first-in-class small molecules and novel vaccines, and advancing them through a virtual, asset-centric subsidiary structure. The company's current pipeline includes a Phase 1 SIK2/3 inhibitor for ovarian cancer and TNBC, an investment in a Phase 2 NMT inhibitor for AML and solid tumors, and a therapeutic vaccine platform for solid tumors. Greenfire's strategy is to build value by providing capital and expert development oversight, then monetizing assets through strategic partnerships, sales, or IPOs.

Therapeutic Areas